The Primary Allegations Plaintiffs in the GLP-1 MDL allege: Failure to warn consumers and doctors about the risks of gastroparesis and intestinal obstruction Design defects in the medications Inadequate post-market surveillance and reaction to adverse events Negligent marketing practices that downplayed serious side effects These claims are supported by growing adverse event reports and emerging studies linking GLP-1 medications to prolonged and debilitating digestive disorders
This is a year-over-year improvement of 30 percentage points, almost doubling after three years
Additionally, the deletion of Meis1, 101 a key transcriptional regulator of the cell cycle and its cofactor Hoxb13, 102 has been found to extend the proliferation window of postnatal cardiomyocytes and reactivate mitosis in adult hearts
However, at least three independent experiments, each containing two or three technical replicates, must be performed for each parameter
, Berlin, Heidelberg: Springer Berlin Heidelberg, pp